Limited sampling strategies for monitoring tacrolimus in pediatric liver transplant recipients

Therapeutic Drug Monitoring

Volumn 33, Issue 4, 2011, Pages 380-386

  Delaloye, Jean Romain ^a,b   Kassir, Nastya ^a,b   Lapeyraque, Anne Laure ^a,b   Alvarez, Fernando ^a   Lallier, Michel ^a   Beaunoyer, Mona ^a   Labbé, Line ^a   Théorêt, Yves ^a,b   Litalien, Catherine ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Limited sampling strategies; Liver transplantation; Pediatrics; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

TACROLIMUS;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOASSAY; INFANT; LIMITED SAMPLING STRATEGY; LIVER GRAFT; MALE; PREDICTION; PRIORITY JOURNAL; SAMPLING; VALIDATION PROCESS;

ADOLESCENT; BLOOD SPECIMEN COLLECTION; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; MALE; REGRESSION ANALYSIS; TACROLIMUS;

EID: 80051796816     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318220bc64     Document Type: Article

References (41)

1. Smith JM, Stablein DM, Munoz R, et al. Contributions of the transplant registry: The 2006 annual report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr Transplant. 2007; 11:366-373. (Pubitemid 46671366)
2. Claeys T, Van Dyck M, Van Damme-Lombaerts R. Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients. Pediatr Nephrol. 2010;25:335-342.
3. Filler G, Feber J, Lepage N, et al. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant. 2002;6:411-418. (Pubitemid 35265193)
4. Filler G, Grygas R, Mai I, et al. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant. 1997;12:1668-1671. (Pubitemid 27346294)
5. Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant. 2007;7:1609-1615. (Pubitemid 46776251)
6. Kim JS, Aviles DH, Silverstein DM, et al. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant. 2005;9:162-169. (Pubitemid 40476842)
7. Lee MN, Butani L. Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation. Pediatr Transplant. 2007; 11:388-393. (Pubitemid 46669059)
8. Montini G, Ujka F, Varagnolo C, et al. The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients. Pediatr Nephrol. 2006;21:719-724.
9. Reding R, Sokal E, Paul K, et al. Efficacy and pharmacokinetics of tacrolimus oral suspension in pediatric liver transplant recipients. Pediatr Transplant. 2002;6:124-126. (Pubitemid 34493031)
10. SchubertM,Venkataramanan R, HoltDW, et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant. 2004;4: 767-773. (Pubitemid 38637576)
11. Shishido S, Asanuma H, Tajima E, et al. Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc. 2001;33: 1066-1068. (Pubitemid 32237749)
12. Wallemacq PE, Furlan V, Moller A, et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet. 1998;23:367-370. (Pubitemid 28517723)
13. Webb NJ, Stevenson PJ, Lewis MA, et al. Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. Transplant Proc. 2002;34:1948-1950.
14. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43: 623-653. (Pubitemid 38981845)
15. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31:139-152.
16. Backman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation. 1994;57:519-525. (Pubitemid 24075796)
17. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62:920-926. (Pubitemid 26360352)
18. Schwartz M, Holst B, Facklam D, et al. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. Transplant Proc. 1995;27:1107.
19. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31:296-298. (Pubitemid 29127464)
20. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 1999;68:55-62. (Pubitemid 29352830)
21. Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit. 2006;28:419-430. (Pubitemid 44314932)
22. Armendariz Y, Pou L, Cantarell C, et al. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit. 2005;27:431-434. (Pubitemid 41098816)
23. Pisitkun T, Eiam-Ong S, Chusil S, et al. The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc. 2002;34:3173-3175. (Pubitemid 35463284)
24. Ragette R, Kamler M,Weinreich G, et al. Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. J Heart Lung Transplant. 2005;24:1315-1319. (Pubitemid 41247815)
25. Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67:2440-2447. (Pubitemid 41623408)
26. Ting LS, Partovi N, Levy RD, et al. Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients. Pharmacotherapy. 2006;26:1232-1240. (Pubitemid 44306882)
27. Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet. 2001;40: 283-295. (Pubitemid 32458154)
28. Manzanares C. Therapeutic drug monitoring of tacrolimus: a moving matter. Therapie. 2002;57:133-136. (Pubitemid 34826875)
29. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporine area under the concentration-time curve: review of current algorithms. Ther Drug Monit. 2001;23:100-114. (Pubitemid 32240136)
30. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
31. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310. (Pubitemid 16134762)
32. Meier-Kriesche HU, Kaplan B, Brannan P, et al. A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation. Ther Drug Monit. 1998;20:401-407. (Pubitemid 28359990)
33. Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus area-underthe- curve monitoring for renal transplant recipients. Am J Kidney Dis. 2000;35:660-666.
34. Dansirikul C, Staatz CE, Duffull SB, et al. Sampling times for monitoring tacrolimus in stable adult liver transplant recipients. Ther Drug Monit. 2004;26:593-599. (Pubitemid 39579139)
35. Langers P, Press RR, den Hartigh J, et al. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration. Ther Drug Monit. 2008;30:456-461.
36. Hoyer PF. Therapeutic drug monitoring of cyclosporin A: should we use the area under the concentration-time curve and forget trough levels? Pediatr Transplant. 2000;4:2-5. (Pubitemid 30064633)
37. Balbontin FG, Kiberd B, Squires J, et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. Transplant Proc. 2003;35: 2445-2448. (Pubitemid 37378028)
38. Jorgensen K, Povlsen J, Madsen S, et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant. 2002;17:1487-1490.
39. Kuypers DR, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004;43:741-762. (Pubitemid 39159005)
40. Miura M, Satoh S, Niioka T, et al. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther DrugMonit. 2008; 30:52-59. (Pubitemid 351161099)
41. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol. 2002;16:253-262. (Pubitemid 35205335)